Literature DB >> 9724173

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.

K R Larsen1, E Z Dajani, N E Dajani, M T Dayton, J G Moore.   

Abstract

Tolcapone (T) is a novel catechol-O-methyltransferase (COMT) inhibitor recently introduced for the treatment of Parkinson's disease. In clinical efficacy studies, T has been associated with a low incidence of diarrhea. The objectives of the study were to examine whether T and its adjunctive drug Sinemet (S) could influence intestinal fluid and electrolyte transport as a possible cause for the diarrhea. The studies were conducted in conscious dogs surgically prepared with Thiry-Vella loops constructed from a 40-cm jejunal segment. A physiologically buffered test solution was perfused into the orad stoma and collected from the caudad stoma. Secretions were collected at 15-min intervals and analyzed for volume, electrolytes, lipid phosphorus, and protein. The acute oral administration of T (10 and 30 mg/kg doses) was well tolerated. Concurrent acute administration of S (25 mg/kg) with T (30 mg/kg) was also well tolerated. The acute oral administration of T induced a dose-dependent efflux of intestinal fluid and electrolytes (sodium, potassium, chloride, and bicarbonate) secretion (P < 0.05). The oral coadministration of S (25 mg/kg) with T (30 mg/kg) accelerated the onset of the stimulation of intestinal secretion. Despite the significant stimulation of intestinal secretion, none of the dogs developed diarrhea, indicating the importance of intestinal compensatory mechanisms. Neither T nor T&S affected calcium, lipid, or protein efflux rates, suggesting that the stimulated secretion was not a consequence of intestinal mucosal injury. The chronic (seven-day) administration of T and T&S was associated with reduced intestinal secretory responses when compared with the acute administration of the same drugs; S enhanced the T-induced tolerance development. The basis for such tolerance is unknown. In conclusion, the stimulatory systemic actions of tolcapone on intestinal secretion may, under certain conditions, contribute to the induction of diarrhea in susceptible patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724173     DOI: 10.1023/a:1018852223902

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors:  H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

2.  Effects of E prostaglandins, diphenoxylate and morphine on intestinal motility in vivo.

Authors:  E Z Dajani; E A Roge; R E Bertermann
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

3.  Microdetermination of plasma phospholipids by trichloroacetic acid precipitation.

Authors:  D B ZILVERSMIT; A K DAVIS
Journal:  J Lab Clin Med       Date:  1950-01

4.  Stimulation of colonic secretion of water and electrolytes by hydroxy fatty acids.

Authors:  P Bright-Asare; H J Binder
Journal:  Gastroenterology       Date:  1973-01       Impact factor: 22.682

5.  Role of gastric mucosal eicosanoid production in the cytoprotection induced by nitecapone.

Authors:  P A Aho; I B Lindén
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

6.  Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.

Authors:  A H Rajput; W Martin; M H Saint-Hilaire; E Dorflinger; S Pedder
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

7.  Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds.

Authors:  G Flemström; B Säfsten; G Jedstedt
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

8.  Catechol-O-methyltransferase and aromatic L-amino acid decarboxylase activities in human gastrointestinal tissues.

Authors:  E Schultz
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

9.  Arsenazo III forms 2:1 complexes with Ca and 1:1 complexes with Mg under physiological conditions. Estimates of the apparent dissociation constants.

Authors:  M V Thomas
Journal:  Biophys J       Date:  1979-03       Impact factor: 4.033

Review 10.  Prostaglandins: an overview of the worldwide clinical experience.

Authors:  E Z Dajani; D E Wilson; N M Agrawal
Journal:  J Assoc Acad Minor Phys       Date:  1991
View more
  2 in total

Review 1.  Small bowel review: normal physiology part 1.

Authors:  A B Thomson; M Keelan; A Thiesen; M T Clandinin; M Ropeleski; G E Wild
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

Review 2.  Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.

Authors:  Carsten Tschöpe; Ahmed Elsanhoury
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.